The experience with the clinical application of liralgutide (victosa), the first analog of human glucagon-like peptide-1 in the patients with type 2 diabetes mellitus - expanding the range of possibilities

Autor:	E I Krasil'nikova, K S Davidenko, E N Ostroukhova, O K Khmel'nitskiĭ
Rok vydání:	2012
Předmět:	medicine.medical_specialty Brand names Liraglutide business.industry Endocrinology Diabetes and Metabolism Type 2 Diabetes Mellitus Hypoglycemic episodes medicine.disease Body weight Obesity Glucagon-like peptide-1 Blood pressure Endocrinology Internal medicine medicine business medicine.drug
Zdroj:	Problems of Endocrinology. 58:51-55
ISSN:	2308-1430 0375-9660
DOI:	10.14341/probl201258351-55
Popis:	This paper reports the results of the treatment of 71 patients presenting with type 2 diabetes mellitus using liraglutide, a long-acting analog of glucagon-like peptide-1 (GLP-1) marketed under the brand name Victoza. Practically all the patients experienced either improvement or normalization of the parameters of carbohydrate metabolism in conjunction with a reduction of their body weight and arterial pressure. There were no severe hypoglycemic episodes and other adverse reactions to the therapy. It is recommended that Victoza should be more widely used for the treatment of the patients with type 2 diabetes mellitus.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::199d6dc080b53dea1931daa5e4cf511c https://doi.org/10.14341/probl201258351-55 Zobrazit plný text záznamu